W81XWH20C0137

THIS AWARD IS FOR THE DELIVERY OF A CGMP MANUFACTURED PRODUCT OF QUANTITY AND QUALITY THAT IT IS SUITABLE AND APPROPRIATE FOR USE IN PIVOTAL CLINICAL STUDIES TO DEMONSTRATE EFFICACY AGAINST ETEC IN ADULTS WITH THE GOAL OF FDA LICENSURE.

Research the contractor View USAspending source Save to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

Field	Reported value
Agency	Department of Defense
Office	ARMY MED RES ACQ ACTIVITY
NAICS	541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSC	Q517 — Pharmacy Services
Parent award / vehicle	Not reported
Set-aside	NO SET ASIDE USED.
Pricing type	FIXED PRICE LEVEL OF EFFORT
Obligations	$44.2M
Current contract value	$51.7M
Potential contract value / ceiling	$51.7M
Start date	Sep 25, 2020
Current end date	Sep 30, 2028
Potential end date	Sep 30, 2028
Latest award activity	Jun 5, 2026
Source loaded	Sep 26, 2026

Funding and modification history

Showing the latest 13 of 13 loaded transactions. Negative values are deobligations.

Date	Modification	Obligation change	Description
Jun 5, 2026	P00012	$0	THIS CONTRACT ACTION IS FOR DIARRHEA PREVENTION FOR TACTICAL ENVIRONMENTS (DPTE).
May 4, 2026	P00011	$1.2M	VACCINE DEVELOPMENT
Feb 13, 2026	P00010	$0	DIARRHEA PREVENTION FOR TACTICAL ENVIRONMENTS
Dec 8, 2025	P00009	$433.3K	THIS CONTRACT ACTION IS FOR DIARRHEA PREVENTION FOR TACTICAL ENVIRONMENTS (DPTE).
May 29, 2025	P00008	$46.0K	CONTRACT FOR DIARRHEA PREVENTION FOR TACTICAL ENVIRONMENTS TESTING AND MANUFACTURE.
Mar 10, 2025	P00007	$606.0K	THIS REQUIREMENT IS FOR THE RESEARCH AND PRODUCTION OF AN ENTEROTOXIGENIC E. COLI VACCINE TO HELP REDUCE WARFIGHTER DOWN TIME WHEN SERVING IN THEATRE.
Sep 18, 2024	P00006	$20.5M	THIS CONTRACT IS FOR THE DEVELOPMENT OF AN E. COLI VACCINE FOR FDA APPROVAL.
Aug 29, 2023	P00005	$254.4K	ENTEROTOXIGENIC E. COLI VACCINE DEVELOPMENT.
Apr 11, 2023	P00004	$0	BASE TASK - SUBCONTRACTORS
Apr 5, 2023	P00003	$5.2M	E. COLI VACCINE DEVELOPMENT.
May 5, 2022	P00002	$4.3M	FURTHER DEVELOPMENT OF ETVAX, A VACCINE AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC).
Oct 28, 2020	P00001	$0	ADMIN MOD CHANGING SEVERAL DELIVERABLE DUE DATES FOUND IN THE AWARD CAUSED BY A DELAYED CONTRACT KICKOFF MEETING.
Sep 25, 2020	0	$8.1M	THIS AWARD IS FOR THE DELIVERY OF A CGMP MANUFACTURED PRODUCT OF QUANTITY AND QUALITY THAT IT IS SUITABLE AND APPROPRIATE FOR USE IN PIVOTAL CLINICAL STUDIES TO DEMONSTRATE EFFICACY AGAINST ETEC IN ADULTS WITH THE GOAL OF FDA LICENSURE.

Estimated positioning window

Sep 30, 2027 – Mar 30, 2028

Recompete signal:

55/100

Why this recompete signal

Contract timing and recorded acquisition signals at the time of calculation.

Stored score: 55/100. Available recorded signals: 50 points.

Contract end 2028-09-30 (706 days from calculation): +25 points
1 historical awards in this buyer and category group: +0 points
13 recorded award transactions: +10 points
Latest award action: 2026-06-05: +5 points
Parent award identifier recorded: +0 points
Solicitation identifier recorded: +10 points
Linked official forecast: +0 points
Calculated on: 2026-10-25 10:18:04.631876+00:00

The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.

Rule-based research score; it does not measure your chance of winning.

This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.

USAspending award record

. Rule-based research score; positioning dates are estimates.

Recompete score calculated Oct 25, 2026.

Research next steps

Check the linked forecast or SAM for a confirmed solicitation and current timing.
Check the stated set-aside against the solicitation and current certifications.
Review the award scope and buyer evidence before making a bid/no-bid decision.